Hofman, K., Shenoy, G. N., Chak, V. & Balu-Iyer, S. V. Pharmaceutical aspects and clinical evaluation of COVID-19 vaccines. Mol. We have reviewed the most apparent and significant differences among the vaccines as far as they can be recognized from published literature, which unfortunately is still incomplete. Sci. 384, 21872201 (2021). Immunol. Effects of pre-existing and vaccination-induced immunity against the vector are a special feature of adenovirus vector vaccines. 21, 637646 (2021). Nat. You are using a browser version with limited support for CSS. The development of COVID-19 vaccines was extremely fast and successful, with several manufacturers having obtained market authorization for their products within the first year from the identification of the virus (SARS-CoV-2). Lancet 397, 671681 (2021). J. Med. 22, 539540 (2021). The RNA in this vaccine is also codon-optimized and contains modifications to improve its performance, butdifferent from the BioNTech-Pfizer and Moderna mRNA vaccines described aboveit does not contain the m1 nucleoside modifications57,58. Nat. The amount of impurities depends on the purification steps applied in the manufacturing process. The viruses are circular in shape with spikes on the surface, which appear like a halo when the virus is viewed with a microscope. Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate. Lancet 396, 479488 (2020). They contain codon-optimized sequences for efficient expression of the full-length S protein and use the authentic signal sequence for its biosynthesis44,45,46,47 (Fig. Bos, R. et al. Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes. Although the animal reservoir for the SARS and MERS viruses are known . CAS Given the same antigenic difference of all vaccines relative to VOCs, the most important parameter determining cross-protection may be the quantity of neutralizing antibodies and relevant cellular immune reactivity at the time of infection. & Stiasny, K. Profiles of current COVID-19 vaccines. They are known to cause diseases including the common cold, Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS) in humans.In January 2020, China saw an outbreak of a new coronavirus strain now named SARS-CoV-2. The uniting feature of current genetic COVID-19 vaccines is the provision of mRNAs for the whole, membrane-anchored spike protein (Figs. Corresponding studies are in progress (Com-Cov study: Oxdorf-AstraZeneca and BionTech-Pfizer, launched in February132). Science 367, 1260 (2020). Vaccines 11, 695719 (2012). The relevance of these differences for protection are not yet clear. Li X, et al. A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. 7, eabe5575 (2021). Commun. J. Med.383, 26032615 (2020). Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant. Currently, a slightly but significantly increased risk of thrombotic events (including cerebral venous sinus thrombosis) was reported after vaccination with Oxford-AstraZeneca and Janssen adenovirus vector vaccines and has raised considerable concern74,75. Lancet 397, 13511362 (2021). The protein has its authentic membrane anchor and remains associated with the membranes of the Sf9 production cells. Some of these mutants are considered Variants of Concern (VOCs) because of their highly efficient transmission, the concomitant replacement of previously circulating strains, and the presence of mutations in the spike protein that can lead to immune escape (https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/). Introduction of two prolines and removal of the polybasic cleavage site lead to higher efficacy of a recombinant spike-based SARS-CoV-2 vaccine in the mouse model. Extremely potent human monoclonal antibodies from COVID-19 convalescent patients. 27, 10551061 (2021). Folegatti, P. M. et al. Science 369, 77 (2020). Mol. Corresponding scientific investigations into the mechanisms of vaccine-induced anaphylactic reactions are ongoing125. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. The addition of a 5 cap structure is a critical part of this production step that has been improved by new technology suitable for large-scale production48,49. Logunov, D. Y. et al. As outlined in the preceding sections, substantial differences appear to exist among current vaccines that can affect the conformation of S and its presentation to the immune system. SPsignal peptide; SRPsignal recognition particle; tPAtissue plasminogen activator; ERendoplasmic reticulum; C-terC terminus; N-terN terminus. Therefore, other adjuvants or combinations thereof with Alum have been developed for use in COVID-19 vaccines138. Article Mol. Coronaviruses were first discovered in the . There is evidence that the Oxford-AstraZeneca vaccine might induce higher levels of specific T cells, whereas mRNA vaccines might induce higher antibody titers115,116,117. The vaccine produced by Bharat is indeed based on a seed virus containing this mutation97 (Table1). 4b)70. c Expression of spike in cells of vaccinated individuals. Nature 583, 290295 (2020). Collectively, there are subtle differences between the two vaccines, both with respect to the RNA and the LNP carriers, and a higher amount of RNA per dose is used in the Moderna vaccine (100g) than in the BioNTech-Pfizer vaccine (30g)46,47. Thank you for visiting nature.com. The vaccine thus presents the correctly folded immunogen in essentially pure form and in combination with a potent adjuvant. Article PubMed 133). Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. While on site, please take precautions to protect yourself and others from Covid-19 by wearing a mask and maintaining social distance as outlined in the Center for Disease Control (CDC) Guidelines. 11, 576622 (2020). a Schematic of the vaccine mRNA in BionTech-Pfizer and Moderna vaccines. People become infected when they then touch their hands to their mouth, nose or eyes. COVID-19 is a contagious respiratory disease caused by infection with the virus SARS-CoV-2. Gao, Q. et al. SARS-CoV-2 vaccine ChAdOx1 nCoV-19 infection of human cell lines reveals low levels of viral backbone gene transcription alongside very high levels of SARS-CoV-2 S glycoprotein gene transcription. N. Engl. & Nauwynck, H. J. Inactivated virus vaccines from chemistry to prophylaxis: merits, risks and challenges. The energy gained by the formation of this hairpin-like structure, in which the fusion peptide is juxtaposed to the C-terminal membrane anchor, is the driving force for viral membrane fusion during entry22. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. 27, 12051211 (2021). This halo of spikes is what led scientists to name these "coronaviruses.". Call the COVID-19 Hotline at. Liang, Z. et al. With these vaccinesand in contrast to genetic vaccinesa predefined amount of the S immunogen/antigen is applied to the vaccinee, butas discussed in the following sectionsits conformational integrity may vary depending on the conditions used for vaccine preparation. Get full coverage of the Coronavirus pandemic including the latest news, analysis, advice and explainers from across the UK and around the world. N. Engl. Coronavirus disease 19 (COVID-19) has resulted in an estimated 470,000 deaths worldwide to date. Rev. Assessing antigen structural integrity through glycosylation analysis of the SARS-CoV-2 viral spike. Article Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. Vaccine 34, 38823893 (2016). Sometimes coronaviruses that infect animals can evolve and make people sick and become a new human coronavirus. A comprehensive review of the global efforts on COVID-19 vaccine development. Lewis, D. Mix-and-match COVID vaccines: the case is growing, but questions remain. Choe, H. & Farzan, M. How SARS-CoV-2 first adapted in humans. Polack, F. P. et al. The effect of dissociation of soluble S1 from the trimer complex on the quality of immune responses is incompletely understood, but some data suggest it may contribute to a higher proportion of non-neutralizing relative to neutralizing antibodies19,81. JAMA 324, 951960 (2020). Med. Nature 594, 483 (2021). Preprint at https://www.researchsquare.com/article/rs-558954/v1 (2021). 48, 6572 (2021). Zhang, Y. et al. For meaningful conclusions, studies on these topics will require head-to-head comparisons of vaccines, and corresponding publications are expected to expand rapidly in the near future. Pardi, N., Hogan, M. J. 7, 586593 (2021). he voted for an austerity budget that reduced health services in the middle of the COVID-19 pandemic. Vaccines (Basel) 9, 65 (2021). So far, no data are available that would allow a direct comparison of the various vaccines and their effectiveness against the different VOCs. These vaccines are now used worldwide for mass immunization programs, and data on vaccine efficacies justify the hope that vaccination can indeed be the main instrument for preventing serious disease and death, and more generally for combating the pandemic1,2,3,4. Heinz, F. X. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. 19, 3546 (2020). The virus that causes COVID-19 is designated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); previously, it was referred to as 2019-nCoV. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. ISSN 2059-0105 (online). In addition, the viral DNA itself can be sensed after endosomal rupture by cytosolic DNA sensors such as cGAS and the inflammasome, resulting in downstream signaling cascades for producing antiviral factors such as type I interferons41. Collectively, this kind of adverse event is designated vaccine-induced immune thrombotic thrombocytopenia (VITT). Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. COVID-19 disease caused by the infection of coronavirus strain SARS-CoV-2. ; Approval of final manuscript: F.X.H. Therefore, it is urgent to know the epidemic . COVID-19 Email. Other components of cellular immunity, such as CD8 T cells, also contribute to immune responses after SARS-CoV-2 infection or vaccination, although their role in COVID-19 infections and protection from disease is still incompletely resolved12,13. Ther. Therefore, for production of the engineered particles as a vaccine, immortalized helper cell lines are used that contain the E1 gene in their chromosomal DNA and provide the missing function, allowing the biosynthesis of structural proteins, replication of modified genomic DNA, and finally assembly of replication-incompetent virus particles in the cells (Fig. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. 178, 104792104792 (2020). According to research published in Rhinology, COVID-19 can cause a loss of taste and smell even without congestion. J. Med. SARS-CoV-2 infection can result in the development of a constellation of persistent sequelae following acute disease called post-acute sequelae of COVID-19 (PASC) or Long COVID 1-3.Individuals diagnosed with Long COVID frequently report unremitting fatigue, post-exertional malaise, and a variety of cognitive and autonomic dysfunctions 1-3; however, the basic biological mechanisms responsible . 65, 1420 (2020). 26, 14221427 (2020). Article 21, 3951 (2021). . Google Scholar. Towards understanding ChAdOx1 nCov-19 vaccine-induced immune thrombotic thrombocytopenia (VITT). Hodgson, S. H. et al. Zhang, J. et al. Indeed, substantially reduced neutralization titers against some VOCs were observed with sera after immunization with mRNA and adenovirus vector vaccines106,107,108,109, pointing to the importance of the problem. Vogel, G. Mixing COVID-19 vaccines appears to boost immune responses. J. Wall, E. C. et al. The past few decades have seen endemic outbreaks in the form of Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute . SARS-CoV-2 (the novel coronavirus that causes coronavirus disease 2019, or COVID-19) People around the world commonly get infected with human coronaviruses 229E, NL63, OC43, and HKU1. J. Med. COVID-19 Hotline. Dolgin, E. CureVac COVID vaccine let-down spotlights mRNA design challenges. In most people, common cold symptoms usually peak within the first two to three days of infection, while the effects of Covid appear two to 14 days after exposure. PubMed Central The second category encompasses protein-based approaches, i.e. The viral RNA is sneaky: its features cause the protein synthesis . Immunol. Tumban, E. Lead SARS-CoV-2 candidate vaccines: expectations from phase III Trials and recommendations post-vaccine approval. Conformational dynamics of SARS-CoV-2 trimeric spike glycoprotein in complex with receptor ACE2 revealed by cryo-EM. PubMed Mol. Details of manufacturing processes may differ between the companies, and subtle product-specific variations of RNA sequences were recently confirmed by comparative analyses of RNA extracted from original vials of the two vaccines (https://github.com/NAalytics/Assemblies-of-putative-SARS-CoV2-spike-encoding-mRNA-sequences-for-vaccines-BNT-162b2-and-mRNA-1273/blob/main/Assemblies%20of%20putative%20SARS-CoV2-spike-encoding%20mRNA%20sequences%20for%20vaccines%20BNT-162b2%20and%20mRNA-1273.docx.pdf). As of mid-March 2022, omicron is the dominant coronavirus variant in the world . The CDC lists these as the most common symptoms of COVID-19: Fever or chills Cough Shortness of breath or difficulty breathing Fatigue Muscle or body aches Headache New loss of taste or smell. d Trimeric post-fusion structure of S2, with the three dissociated S1 subunits, shaded in light colors. Kowarz, E. et al. 12, 372 (2021). Sensors in the cytoplasm, such as retinoic-inducible gene I (RIG-I) and melanoma differentiation-associated antigen 5 (MDA-5) recognize preferentially dsRNA, also leading to stimulation of type I IFN secretion134,135. In the CanSino vaccine, the signal peptide of S is replaced by that of human tPA (https://patents.google.com/patent/CN111218459B/en). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. BMJ 373, n969 (2021). In this case, seropositivity is negligible in Europe (zero in the UK,64) and low in Africa (9% in Gambian adults,64,131). This quantitative aspect is important for future analyses of the impact of waning immunity on protection and decisions about optimal timings of booster immunizations. ; Visualization: F.X.H. This classification was based on the following: Detection of cases attributed to Omicron in multiple countries, including among those without travel history. Greinacher, A. et al. Infect Cont Hosp Epidemiol 2022; 43: 12 - 25. ACS Central Sci. PubMed Center for Virology, Medical University of Vienna, Vienna, Austria, You can also search for this author in Med. N. Engl. J. Med. COVID-19, short for "coronavirus disease 2019," is caused by the novel coronavirus SARS-CoV-2. The precise mechanisms of how the RNA is taken up by different cells after vaccination and escapes from LNPs and intracellular vesicles is incompletely resolved53,55. 41). Quantitative recovery of adenoviral vector particles involves lysis of the cells by detergents (Fig. 2d)24,25,26. 100, 309354 (2018). Bottermann, M. & James, L. C. Intracellular antiviral immunity. Verbeke, R., Lentacker, I., De Smedt, S. C. & Dewitte, H. The dawn of mRNA vaccines: The COVID-19 case. Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation. Variations include (but are not limited to) the type of adenovirus used as a vector, genetic modifications of the vector, the cell lines used for vaccine production, procedures for purification, and the specific design of the gene for expressing S (Table1). SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. This is why it's very important that we socially distance from other people, and wear a mask. It consists of the trimeric full-length spike that is produced as a recombinant protein in insect Sf9 (Spodoptera frugiperda) cells using a baculovirus expression system and contains mutations to stabilize S2 (K986P and V987P) as well as to delete the furin cleavage site (682-RRAS-685 changed to QQAQ)99 (Table1 and Fig. https://doi.org/10.1038/s41591-021-01413-7 (2021). Vaidyanathan, S. et al. 80). And like other coronaviruses that infect people, the new coronavirus causes respiratory disease, among other symptoms. Zeng, C., Zhang, C., Walker, P. G. & Dong, Y. Formulation and delivery technologies for mRNA vaccines. In the meantime, to ensure continued support, we are displaying the site without styles McCoy, K. et al. J. Med. Persistence of RNA and its expression after different routes of application (including intramuscular) appears to be short (at least in mice), with a maximum of 10 days60. Details of the engineered leader sequence in the ChAdOX1-S vaccine are difficult to track, but likely comprise 32 to 34 amino acids of tPA (according to a document of the European Medicines Agency assessing thrombotic post-vaccination events, EMA/205598/2021) and may contain a P to A mutation at position 22 to improve processing by signal peptidase80. The authors declare no competing interests. Both modifications are intended to avoid conversion of S into the post-fusion structure (Fig. Xu, C. et al. Trends Biochem. 8, 654866 (2021). Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Correlates of protection against SARS-CoV-2 in rhesus macaques. JAMA 325, 15621565 (2021). Both mRNA vaccines have modulated 5 and 3 untranslated sequences to optimize mRNA stability and translation efficiency44,45, and all uridines are replaced by N1-methylpseudouridine (m1) to further increase RNA stability and to reduce innate immune responses (Fig. Hum. Patent WO/2018/215766 (WIPO IP Portal, 2018). This enormous progress was achieved with fundamentally different vaccine technologies used in parallel. Published information about the production process is available for two inactivated whole-virus vaccines manufactured by the Chinese companies Sinopharm and Sinovac (Table1). RBDreceptor binding domain; NTDN-terminal domain; FPfusion peptide. Evidence for antibody as a protective correlate for COVID-19 vaccines. . Rev. 17, 261279 (2018). A severe complication of COVID-19 is viral pneumonia. Distinguishing characteristics and unknown features are highlighted in the context of protective antibody responses and reactogenicity of vaccines. 1b). 26, 311323 (2020). The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. While these efforts resulted in successful classification systems, the design of a portable and cost-effective COVID-19 diagnosis system has not been addressed yet. Science https://doi.org/10.1126/science.abj9106 (2021). Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. After vaccination with mRNA vaccines, rare events of anaphylactic shock above the average incidence in the population have been reported, largely in individuals with a history of allergy123,124. In one study they collected 15 false and 15 true headlines about Covid-19. Robbiani, D. F. et al. 10, 28752884 (2014). Voss, W. N. et al. Irrespective of pre-existing immunity, all adenovirus vector vaccines are prone to induce immune responses against the vector particles129. Preprint at https://www.biorxiv.org/content/10.1101/2021.04.20.440647v2 (2021). Except for mRNA vaccines, different eukaryotic cell cultures are used in the production of current COVID-19 vaccines (see sections Biosynthesis and key properties of the spike protein and Vaccine-specific differences of S-antigen structure and presentation and Table1). Slider with three articles shown per slide. Thiagarajan, K. Covid-19: India is at centre of global vaccine manufacturing, but opacity threatens public trust. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. In conclusion, since the emergence of COVID-19 pneumonia and due to its similar radiological patterns, we believe that a SARS-CoV-2 RT-PCR should be systematically realized in case of respiratory . a Schematic of replication-incompetent adenoviral vector particle and its DNA. Lancet 396, 467478 (2020). An infection often resolves quickly and can appear similar to food poisoning. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans, Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic, SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates, COVID-19 vaccines: where we stand and challenges ahead, Comparative analysis of COVID-19 vaccine responses and third booster dose-induced neutralizing antibodies against Delta and Omicron variants, Versatility of live-attenuated measles viruses as platform technology for recombinant vaccines, ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants, A randomized controlled trial of heterologous ChAdOx1 nCoV-19 and recombinant subunit vaccine MVC-COV1901 against COVID-19, Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19, https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines, https://github.com/NAalytics/Assemblies-of-putative-SARS-CoV2-spike-encoding-mRNA-sequences-for-vaccines-BNT-162b2-and-mRNA-1273/blob/main/Assemblies%20of%20putative%20SARS-CoV2-spike-encoding%20mRNA%20sequences%20for%20vaccines%20BNT-162b2%20and%20mRNA-1273.docx.pdf, https://www.curevac.com/en/2021/06/16/curevac-provides-update-on-phase-2b-3-trial-of-first-generation-covid-19-vaccine-candidate-cvncov/, https://www.who.int/publications/m/item/considerations-for-the-assessment-of-covid-19-vaccines-for-listing-by-who, https://patents.google.com/patent/CN111218459B/en, https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/, https://www.biorxiv.org/content/10.1101/2021.04.20.440647v2, https://doi.org/10.1038/s41591-021-01413-7, https://www.medrxiv.org/content/10.1101/2020.11.09.20228551v1, https://www.researchsquare.com/article/rs-558954/v1, https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2018215766, https://doi.org/10.1016/s0140-6736(21)01462-8, https://doi.org/10.1038/s41586-021-03777-9, https://www.medrxiv.org/content/10.1101/2021.05.07.21256809v1, https://www.researchsquare.com/article/rs-440461/v1, https://doi.org/10.1080/08820139.2021.1904977, https://www.biorxiv.org/content/10.1101/2021.04.14.439844v1, http://creativecommons.org/licenses/by/4.0/, Baculovirus displaying SARS-CoV-2 spike RBD promotes neutralizing antibody production in a mouse model, Comparative effectiveness of BNT162b2 and ChAdOx1 nCoV-19 vaccines against COVID-19, COVID-19 vaccines adverse events: potential molecular mechanisms, Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine, SARS-Cov-2 incubation period according to vaccination status during the fifth COVID-19 wave in a tertiary-care center in Spain: a cohort study, COVID-19 two years on: development and implementation of vaccines against SARS-CoV-2.